- Home
- VRTX
as 05-20-2024 10:33am EST
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
| Founded: | 1989 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 114.9B | IPO Year: | 1991 |
| Target Price: | $441.40 | AVG Volume (30 days): | 1.0M |
| Analyst Decision: | Buy | Number of Analysts: | 25 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 15.41 | EPS Growth: | 22.79 |
| 52 Week Low/High: | $320.01 - $448.40 | Next Earning Date: | 05-06-2024 |
| Revenue: | $10,185,000,000 | Revenue Growth: | 10.61% |
| Revenue Growth (this year): | 10.73% | Revenue Growth (next year): | 9.36% |
Share on Social Networks:
Stock Insider Trading Activity of Vertex Pharmaceuticals Incorporated (VRTX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| ALTSHULER DAVID | VRTX | EVP, Chief Scientific Officer | May 15 '24 | Sell | $430.93 | 54 | $23,270.22 | 25,813 | SEC Form 4 |
| Arbuckle Stuart A | VRTX | EVP, COO | May 15 '24 | Sell | $430.93 | 69 | $29,734.17 | 49,691 | SEC Form 4 |
| Ambrose Kristen | VRTX | SVP & Chief Accounting Officer | Apr 1 '24 | Sell | $419.00 | 240 | $100,560.00 | 7,500 | SEC Form 4 |
| Arbuckle Stuart A | VRTX | EVP, COO | Feb 23 '24 | Sell | $425.70 | 5,034 | $2,142,973.80 | 49,691 | SEC Form 4 |
| Ambrose Kristen | VRTX | SVP & Chief Accounting Officer | Feb 23 '24 | Sell | $425.70 | 883 | $375,893.10 | 7,965 | SEC Form 4 |
| Tatsis Ourania | VRTX | EVP, Chief Reg. & Quality Off. | Feb 23 '24 | Sell | $425.70 | 354 | $150,697.80 | 55,804 | SEC Form 4 |
| Sachdev Amit | VRTX | EVP Chief Patient & Ext Af Off | Feb 23 '24 | Sell | $425.70 | 3,004 | $1,278,802.80 | 55,325 | SEC Form 4 |
| Atkinson Edward Morrow III | VRTX | EVP, Chief Technical Ops. Off. | Feb 23 '24 | Sell | $425.70 | 883 | $375,893.10 | 15,972 | SEC Form 4 |
| Arbuckle Stuart A | VRTX | EVP, COO | Feb 21 '24 | Sell | $421.77 | 3,603 | $1,519,637.31 | 59,439 | SEC Form 4 |
| Tatsis Ourania | VRTX | EVP, Chief Reg. & Quality Off. | Feb 21 '24 | Sell | $421.77 | 360 | $151,837.20 | 59,467 | SEC Form 4 |
| ALTSHULER DAVID | VRTX | EVP, Global Research and CSO | Feb 21 '24 | Sell | $421.77 | 3,002 | $1,266,153.54 | 34,022 | SEC Form 4 |
| Sachdev Amit | VRTX | EVP Chief Patient & Ext Af Off | Feb 21 '24 | Sell | $421.77 | 3,191 | $1,345,868.07 | 60,798 | SEC Form 4 |
| Atkinson Edward Morrow III | VRTX | EVP, Chief Technical Ops. Off. | Feb 21 '24 | Sell | $421.77 | 1,201 | $506,545.77 | 18,509 | SEC Form 4 |
| Sachdev Amit | VRTX | EVP Chief Patient & Ext Af Off | Feb 16 '24 | Sell | $420.79 | 4,254 | $1,790,040.66 | 63,989 | SEC Form 4 |
| Atkinson Edward Morrow III | VRTX | EVP, Chief Technical Ops. Off. | Feb 16 '24 | Sell | $420.79 | 801 | $337,052.79 | 19,710 | SEC Form 4 |
| Arbuckle Stuart A | VRTX | EVP, COO | Feb 16 '24 | Sell | $420.79 | 4,804 | $2,021,475.16 | 63,042 | SEC Form 4 |
| ALTSHULER DAVID | VRTX | EVP, Global Research and CSO | Feb 16 '24 | Sell | $420.79 | 4,002 | $1,684,001.58 | 37,024 | SEC Form 4 |
| Tatsis Ourania | VRTX | EVP, Chief Reg. & Quality Off. | Feb 16 '24 | Sell | $420.79 | 480 | $201,979.20 | 59,827 | SEC Form 4 |
| LEIDEN JEFFREY M | VRTX | Executive Chairman | Feb 14 '24 | Sell | $419.04 | 4,356 | $1,825,338.24 | 22,551 | SEC Form 4 |
| LEIDEN JEFFREY M | VRTX | Executive Chairman | Feb 14 '24 | Sell | $419.16 | 4,655 | $1,951,189.80 | 17,896 | SEC Form 4 |
| Biller Jonathan | VRTX | EVP and Chief Legal Officer | Feb 9 '24 | Sell | $418.77 | 1,738 | $727,822.26 | 18,280 | SEC Form 4 |
| Arbuckle Stuart A | VRTX | EVP, COO | Feb 9 '24 | Sell | $420.24 | 4,295 | $1,804,930.80 | 75,718 | SEC Form 4 |
| Ambrose Kristen | VRTX | SVP & Chief Accounting Officer | Feb 9 '24 | Sell | $420.24 | 1,374 | $577,409.76 | 9,676 | SEC Form 4 |
| Tatsis Ourania | VRTX | EVP, Chief Reg. & Quality Off. | Feb 9 '24 | Sell | $420.24 | 314 | $131,955.36 | 68,179 | SEC Form 4 |
| Sachdev Amit | VRTX | EVP Chief Patient & Ext Af Off | Feb 9 '24 | Sell | $420.24 | 3,222 | $1,354,013.28 | 74,364 | SEC Form 4 |
Latest Vertex Pharmaceuticals Incorporated News
VRTX Breaking Stock News: Dive into VRTX Ticker-Specific Updates for Smart Investing
Motley Fool
3 days ago
Is CRISPR Therapeutics Stock a Buy?
Motley Fool
5 days ago
Is CRISPR Stock Going to $95? 1 Wall Street Analyst Thinks So.
Business Wire
5 days ago
Jennifer Schneider Elected to Vertex Board of Directors
Investor's Business Daily
6 days ago
Vertex Stock Hit All-Time High, Paused, Rising Again
Zacks
6 days ago
Here's Why Vertex Pharmaceuticals (VRTX) is a Strong Growth Stock
MT Newswires
6 days ago
Wolfe Research Adjusts Price Target on Vertex Pharmaceuticals to $520 From $497
Argus Research
7 days ago
Technical Assessment: Bullish in the Intermediate-Term
Motley Fool
8 days ago